The active ingredient, tirzepatide, engages two receptors, GIP and GLP-1. These are the receptors for two hormones the digestive system produces after eating, hormones that influence appetite and blood sugar. It is the medication at the center of Bodi Envi's Personalized Compounded Tirzepatide Weight-Management Programs for people in the Detroit metro.
Personalized Compounded Tirzepatide is a version of that active ingredient prepared by a licensed compounding pharmacy from a prescription written for an individual patient. It is taken as a weekly injection, and the starting dose and any later change are decided by the prescribing provider, not by the patient and not by Bodi Envi.
Personalized Compounded Tirzepatide is not FDA-approved and is not equivalent to the FDA-approved products that contain the same active ingredient, Mounjaro® and Zepbound®. The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, which is why a licensed provider decides case by case whether treatment is appropriate. Brand names are trademarks of their respective owners. Compounding pharmacies are regulated by state boards of pharmacy for sterile compounding and are required to follow United States Pharmacopeia standards.